UNCLAIMED
Illumina, Inc.
Overview
Illumina, Inc. is a biotechnology and pharmaceuticals company based in the USA, employing approximately 8,970 individuals and generating revenues of $4,372 million. The company specializes in next-generation sequencing (NGS) and microarray technologies, focusing on applications in cancer research and genomics. Its published materials include comprehensive guides and case studies that detail methodologies for utilizing NGS in cancer research, emphasizing the importance of various genomic and epigenomic techniques. The guides outline workflows for NGS, including nucleic acid isolation, library preparation, and data analysis, thereby providing end-to-end solutions for researchers. Additionally, Illumina's documentation highlights specific methods such as whole-genome sequencing (WGS) and methylation arrays, which are integral to understanding cancer biology. The company also produces technical notes that support population genomics, further illustrating its commitment to advancing genomic research. Overall, Illumina's focus on innovative sequencing technologies positions it as a key player in the biotech industry, particularly in the realm of cancer genomics and research methodologies.